The efficacy of immune checkpoint therapy in pMMR/MSS TYPE ICC is unclear, and the prognostic effect of TMB and PDL-1 expression status has not been concluded [84–86]. This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.